## UK122

Colo No.		
Cat. No.:	HY-111056	
CAS No.:	940290-58-4	
Molecular Formula:	C <sub>17</sub> H <sub>13</sub> N <sub>3</sub> O <sub>2</sub>	NH
Molecular Weight:	291.3	P-PO NH2
Target:	Ser/Thr Protease	
Pathway:	Metabolic Enzyme/Protease	
Storage:	-20°C, protect from light, stored under nitrogen * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)	

## SOLVENT & SOLUBILITY

In Vitro	DMSO : 14.29 mg/mL (49.06 mM; Need ultrasonic)					
	Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg	
		1 mM	3.4329 mL	17.1644 mL	34.3289 mL	
		5 mM	0.6866 mL	3.4329 mL	6.8658 mL	
		10 mM	0.3433 mL	1.7164 mL	3.4329 mL	
	Please refer to the solubility information to select the appropriate solvent.					
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 1.43 mg/mL (4.91 mM); Clear solution					
	2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 1.43 mg/mL (4.91 mM); Clear solution					
	3. Add each solvent o Solubility: ≥ 1.43 n	one by one: 10% DMSO >> 90% cor ng/mL (4.91 mM); Clear solution	n oil			

Dideosical Activity				
Description	UK122 is a potent and selective urokinase-type plasminogen activator (uPA) inhibitor with an IC <sub>50</sub> of 0.2 μM. UK122 shows no or little inhibition of tissue-type PA (tPA), plasmin, thrombin, and trypsin (all IC <sub>50</sub> >100 μM). UK122, 4-oxazolidinone analogue, is an anticancer agent and inhibits cancer cell migration and invasion <sup>[1]</sup> .			
In Vitro	UK122 (11.1, 33.3, 100 μM; 24 h) dose-dependently inhibits cell migration and significantly reduces the invasiveness of CFPAC-1 cells <sup>[1]</sup> . UK122 (10-100 μM; 48 h) has no effect of any cell growth or cell morphology change in CFPAC-1 cells <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.			



## REFERENCES

[1]. Ming Zhu, et al. Identification of a novel inhibitor of urokinase-type plasminogen activator. Mol Cancer Ther. 2007 Apr;6(4):1348-56.

## Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA